Sarepta Therapeutics to Present at Upcoming Investor Conferences
Sarepta Therapeutics (NASDAQ:SRPT) announced that senior management will participate in two investor conferences on Nov. 9, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
- 8th Annual Wolfe Research Healthcare Conference in
New York City - Guggenheim Securities 3rd Annual Healthcare Innovation Conference in
Boston - Fireside chat: 3 p.m. ET
The presentation from the Guggenheim conference will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261026409334/en/
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Ryan Wong, 617-800-4112
rwong@sarepta.com
Tam Thornton, 617-803-3825
tthornton@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.